featured-stories Archives - Crexont Site

Derek’s care partner journey: Parkinson’s, partnership, and the power of the right treatment

“Sam’s story is unfolding. And every chapter reminds me of how strong, funny, and brilliant she is. Parkinson’s doesn’t define her; it’s just one part of our story. “

Meet Dr Morgan: From treating Parkinson’s to living with it

“I tell them, ‘I’ve had Parkinson’s for 5 years. Do I look okay to you?’ And they say, ‘Yeah, you do.’ That moment gives me hope.”

Laura’s story: Redefining life with Parkinson’s

“Parkinson’s doesn’t stop me from being myself. If anything, it’s made me more intentional [with my time].”

Meet Lori: Finding freedom and balance in the Parkinson’s journey

“I’ve always been positive and upbeat—it killed me to say I didn’t feel good,” Lori says. “These days, I feel more comfortable and more like myself in my routine.”

Navin’s journey: How music, movement, and positivity shaped his path with Parkinson’s

“We’re all on this journey together. And if I can help someone feel even a little less afraid of the future, then I’ve done what I set out to do.”

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
Experience hallucinations or abnormal thoughts and behaviors
Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
Have thoughts of suicide or have attempted suicide
Have abnormal involuntary movements that appear or get worse during treatment
Have ever had a peptic ulcer or glaucoma
Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
Are breastfeeding during therapy

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA⁠-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
Experience hallucinations or abnormal thoughts and behaviors
Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
Have thoughts of suicide or have attempted suicide
Have abnormal involuntary movements that appear or get worse during treatment
Have ever had a peptic ulcer or glaucoma
Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
Are breastfeeding during therapy

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA⁠-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC. © 2025 Amneal Pharmaceuticals LLC.

Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.

All rights reserved. PP-IPX203-US-0026 06/2025

This is intended for residents of the United States only. Any product discussed herein may have different product labeling in different countries. Please read the full Prescribing Information and discuss it with your doctor or healthcare professional.